Leap Therapeutics Initiates 130 Patient Randomized Controlled Part B Of The Phase 2 Study
Portfolio Pulse from Benzinga Newsdesk
Leap Therapeutics has initiated the randomized controlled Part B of its Phase 2 study, which involves 130 patients. The study is evaluating Leap's DKN-01 antibody in combination with standard of care bevacizumab and chemotherapy as a second-line treatment for patients with advanced CRC.
July 12, 2023 | 11:04 am
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Leap Therapeutics is advancing its Phase 2 study, which could potentially impact its stock depending on the results of the study.
The initiation of Part B of the Phase 2 study by Leap Therapeutics is a significant step in the development of its DKN-01 antibody. The results of this study could potentially impact the company's stock price, either positively if the results are promising, or negatively if the results are not as expected. However, as the results are not yet known, the short-term impact on the stock is neutral.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100